-
Long PFE At $19.39
Tuesday, March 1, 2011 - 12:57pm | 84Only one trade so far, and I took it in Pfizer (PFE). But I am looking at a few others that are very intriguing - Netflix (NFLX) is one of them, with it currently testing the 50-day moving average, it could see a sizable bounce. Here's the chart analysis and setup on PFE. Read more...
-
Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot
Tuesday, March 1, 2011 - 12:45pm | 162Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Vivelle Ventures LLC, Noven Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for...
-
Bristol-Myers Squibb Names Elliott Sigal to Board of Directors
Tuesday, March 1, 2011 - 12:42pm | 46Bristol-Myers Squibb Company (NYSE: BMY) today announced that Elliott Sigal, M.D., Ph.D., has been elected to its Board of Directors, effective today. Dr. Sigal also will be a member of the Board's Science and Technology Committee.
-
Bull Pa Ba Or Bear Na Ba??? – A Market Forum
Tuesday, March 1, 2011 - 11:31am | 475Bull pa ba or bear na ba??? Absolute Traders will be having a Chart & Fundamental Analysis Forum on March 25. OPEN TO ALL. Special Guests: First Metro Investment Corporation (Gus Cosio and Juni Banaag), surprise guests from different companies, LaidTrades (Ron Acoba and...
-
Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
Tuesday, March 1, 2011 - 10:31am | 47Perrigo (Nasdaq: PRGO) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the Detroit Office of the Food and Drug Administration (FDA) has arrived at their Allegan facility for the re-inspection.
-
Pfizer Completes Acquisition Of King Pharmaceuticals
Tuesday, March 1, 2011 - 9:14am | 124Pfizer Inc. (NYSE: PFE) today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary...
-
Bristol-Myers Squibb's BARACLUDE Approved by the European Commission for the Treatment of Chronic Hepatitis B
Tuesday, March 1, 2011 - 9:09am | 91Bristol-Myers Squibb (NYSE: BMY) announced today that BARACLUDE (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006...
-
Piper Jaffray Comments On Salix Pharmaceuticals Following Recent Earnings Report
Tuesday, March 1, 2011 - 8:49am | 196Last night, Salix Pharmaceuticals (NASDAQ: SLXP) reported non-GAAP diluted EPS of $0.66, handily beating the Street estimate of $0.49. Xifaxan sales of $83M were in line with Piper Jaffray's estimate. We believe that management guided conservatively for 2011, and continue to believe there is...
-
Robert J. Cindrich and Heather Bresch Appointed to Mylan's Board
Tuesday, March 1, 2011 - 8:39am | 47Mylan Inc. (Nasdaq: MYL) today announced that its Board of Directors has voted unanimously to appoint Robert J. Cindrich and Heather Bresch to Mylan's Board. With the appointments of Cindrich and Bresch, Mylan has expanded its board to 11 members.
-
Goldman Discusses Salix Pharmaceuticals, Ltd. (SLXP)
Tuesday, March 1, 2011 - 8:38am | 139Goldman Sachs has a note on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) after it reported earnings. It has a Neutral rating and a $37 price target on shares. In a note to clients, Goldman writes, "We maintain our Neutral rating with a still strong growth outlook providing support for shares, but...
-
Oppenheimer Has Outperform On Salix Pharmaceuticals (SLXP)
Tuesday, March 1, 2011 - 8:32am | 137Oppenheimer & Co. has an Outperform rating and a $46 price target on shares of Salix Pharmaceuticals (NASDAQ: SLXP) after it reported earnings. In a note to clients, Oppenheimer writes, "On 2/28, SLXP reported 4Q10 adjusted EPS of $0.64 compared to our estimate of $0.48. Importantly, total...
-
Akorn Reports Q4 EPS of $0.23
Tuesday, March 1, 2011 - 8:31am | 83Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2010. Consolidated revenue for the fourth quarter of 2010 was $24.0 million, up 32% over the prior year quarter consolidated revenue of $18.2...
-
Teva Announces Trial Date in Generic COPAXONE Litigation
Tuesday, March 1, 2011 - 8:24am | 68Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and...
-
UPDATE: Piper Jaffray Color On ENDP 4Q
Tuesday, March 1, 2011 - 8:21am | 156Piper Jaffray, which raised its PT on shares of Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), is providing some color on the stock. “Yesterday, Endo reported 4Q10 adjusted diluted EPS of $1.06, well ahead of the Street estimate of $0.97,” Piper Jaffray writes. “Total revenues of $511M, were...
-
Piper Jaffray Raises PT On Endo Pharmaceuticals To $40
Tuesday, March 1, 2011 - 8:05am | 27Piper Jaffray has raised the price target on Endo Pharmaceuticals (NASDAQ: ENDP) from $39 to $40 and maintains its Neutral rating.